E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
obsessive compulsive disorder (OCD) |
|
E.1.1.1 | Medical condition in easily understood language |
obsessive compulsive disorder |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10002862 |
E.1.2 | Term | Anxiety disorders NEC (incl obsessive compulsive disorder) |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of AFQ056 (16 weeks treatment), using Y-BOCS change from baseline compared with placebo |
|
E.2.2 | Secondary objectives of the trial |
• To assess the effect of AFQ056, after 16 weeks treatment, on OCD as
measured by Y-BOCS response rates, Clinical Global Impression of
Improvement (CGI-I) and Clinical Global Impression of Severity (CGI-S)
• To assess the effect of AFQ056, after 16 weeks treatment, on global
social functioning using Sheehan Disability Scale (SDS)
• To assess the effect of AFQ056, after 16 weeks treatment, on
depression as measured by the Hamilton Depression Scale (HAMD-17)
• To assess the effect of AFQ056, after 16 weeks treatment, on anxiety
as measured by the Hamilton Anxiety Scale (HAM-A)
• To assess the effect of AFQ056, after 16 weeks treatment, on cognition
in OCD patients as measured by Cogstate
• To assess the safety and tolerability of multiple titrated oral doses of
AFQ056
• To evaluate the pharmacokinetics of AFQ056 in Patients with OCD |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients eligible for inclusion in this study have to fulfill all of the
following criteria:
1. Male and female, non-smokers patients aged between 18 to 65 years
(inclusive),
2. A primary diagnosis of obsessive-compulsive disorder (OCD) as per
Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR 4th ed, year 2000), as
confirmed by
an Independent Rater.
3. Be on a stable appropriate dose of selective serotonin reuptake
XML File Identifier: AxYNYso9SmTEJM9rIA71enqiz6g=
Page 18/34
inhibitor (SSRI) treatment for at least 12 weeks prior to Baseline.
4. Have an insufficient response to current SSRI treatment (as per
Inclusion Criterion 4) and confirmed by an Independent Rater.
Note: Treatment with SSRI and related time period must be documented
in the medical records of the patient (e.g. former prescription, former
medical records). Note that
patient self report is not acceptable.
5. Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) of score ≥
20 at Screening (and confirmed by an Independent Rater).
6. Patient must have their eligibility confirmed following the remote (or
face to face)
interview conducted by the Independent Rater.
7. Able to communicate well with the investigator, to understand and
comply with the requirements of the study. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria in this study:
1. Diagnosis of primary OCD symptom of hoarding.
2. History of more than two unsatisfactory trials with different serotonin reuptake inhibitors within a period of 2 years prior to screening (not including the current treatment with SSRI's given in an dequate dose for at least 12 weeks).
3. Diagnosed with any primary DSM-IV-TR Axis I disorder other than OCD (as confirmed by an Independent Rater); with the exception of depression (refer to criterion 4).
4. Moderate - severe depression, as assessed with a HAM-D score >16 and response to the ATRQ (as confirmed by an Independent rater) at Screening.
5. History eating disorder according to DSM-IV within the last 6 months prior to Screening
6. Diagnosed with antisocial personality disorder (DSM-IV-TR Axis II), as confirmed by an ndependent Rater.
7. Has current or past medical history of bipolar disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism (with exception of high-functioning or autistic spectrum disorders e.g. Asperger’s Syndrome), borderline personality disorder, or Gilles de la Tourette syndrome within the last 6 months prior to Screening.
8. Smokers (use of tobacco products in the previous 3 months)
9. History (lifetime) of hallucinations/psychosis that would require
antipsychotic treatment or DSM-IV criteria being met
10. Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the
C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any
item of the Suicidal Behavior section, except for the "Non-Suicidal Self-
Injurious Behavior" (item also included in the Suicidal Behavior section),
if this behavior occurred in the past 2 years.
11. Women of child-bearing potential, defined as all women
physiologically capable of becoming pregnant, unless they are using
highly effective methods* of contraception during dosing and for 30 days
after last dosing of study medication.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Absolute changes from baseline for Y-Bocs |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Absolute changes from baseline for Y-Bocs at week 17 (end of 16 week dosing) |
|
E.5.2 | Secondary end point(s) |
effect on OCD as measured by Y-BOCS response rates, if a subject demonstrates at least 25%
reduction in total Y-BOCS from Baseline then they will be classed as a responder whereas if a
subject has a reduction in Y-BOCS of less than 25% then they will be categorized as a non-responder, Clinical Global Impression of Improvement (CGI-I), Clinical Global Impression of Severity (CGI-S)
effect on global social functioning using Sheehan Disability Scale (SDS)
effect on depression as measured by the Hamilton Depression Scale
(HAMD-17)
effect on anxiety as measured by the Hamilton Anxiety Scale (HAM-A)
effect of AFQ056 on cognition in OCD patients as measured by Cogstate safety and tolerability of multiple titrated oral doses of AFQ056 pharmacokinetics of AFQ056 in Patients with OCD |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
after 16 weeks treatment:
effect on OCD as measured by Y-BOCS response rates, Clinical Global Expression of Improvement (CGI-I), Clinical Global Expression of Severity (CGI-S) and Obsessive-Compulsive Inventory-Revised (OCI-R)
effect on global social functioning using Sheehan Disability Scale (SDS)
effect on depression as measured by the Hamilton Depression Scale (HAMD-17)
effect on anxiety as measured by the Hamilton Anxiety Scale (HAM-A)
effect of AFQ056 on cognition in OCD patients as measured by Cogstate during overall trial: safety and tolerability of multiple titrated oral doses of AFQ056 pharmacokinetics of AFQ056 in Patients with OCD |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
This study is designed as a Proof of Concept of AFQ056 in Obsessive Compulsive Disorder (OCD). The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have eneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to SSRI treatment (failed SSRI over 12 weeks at appropriate doses). |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 36 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
Canada |
Czech Republic |
France |
Germany |
Italy |
Poland |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |